CorMedix (CRMD) FCF Margin (2015 - 2025)

CorMedix (CRMD) posted FCF Margin of 72.11% for Q4 2025, up 147.74% sequentially from 29.11% in Q3 2025, and up 9013.0% YoY from 0.79% in Q4 2024.

CorMedix (CRMD) FCF Margin (2015 - 2025) Analysis & Trends

CorMedix has reported FCF Margin for 10 years, with the latest figure at 72.11% in Q4 2025.

Quarterly FCF Margin rose 9013.0% year-over-year to 72.11% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 55.43% (up 17205.0% YoY) and the FY2025 annual result came in at 55.43%, up 17213.0% from the prior year.
FCF Margin grew to 72.11% in Q4 2025 per CRMD's latest filing, from 29.11% in the prior quarter.
Over five years, FCF Margin peaked at 75.42% in Q2 2025 and troughed at 89069.3% in Q3 2022.
A 4-year average of 19961.88% and a median of 7595.53% in 2021 frame the typical range for FCF Margin.
The widest YoY moves for FCF Margin: up 1206455 bps in 2022, down 8078407 bps in 2022.
Over 4 years, FCF Margin stood at 11522.1% in 2021, then sank by 84 bps to 21155.46% in 2022, then surged by 100 bps to 18.02% in 2024, then surged by 500 bps to 72.11% in 2025.
According to Business Quant data, FCF Margin over the past three periods registered 72.11%, 29.11%, and 75.42% for Q4 2025, Q3 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	30.39%
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	13.35%
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-388.28%
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	25.68%
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	22.62%
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	41.07%
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-22.35%
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	70.82%
10	CorMedix	645.20 Mn	388.51 Mn	77.13 Mn	-

Download Data